Physician profile
Brian K Way
NPI 1538123476
$8,254.19
in general payments reported to CMS, 2019-2025
42 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $723 · 2021: $764 · 2022: $1,142 · 2023: $1,445 · 2024: $1,322 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,395.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.90 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $795.52 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $781.73 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $651.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $527.20 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $526.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $521.21 | 2019-2023 | Xarelto, Spravato |
| Pfizer INC. | $480.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.72 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.58 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $247.11 | 2021-2024 | |
| Esperion Therapeutics, INC. | $203.22 | 2020-2025 | Nexletol |
| Allergan, INC. | $194.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $191.48 | 2019-2023 | |
| Lundbeck LLC | $168.42 | 2022-2025 | Vyepti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Way listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.